Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486664 | 0.84 | MAPT (0.40) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL16119715 | 0.83 | TSHR (0.42) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL20392801 | 0.83 | L3MBTL1 (0.41) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL28024347 | 0.80 | SMN1; SMN2 (0.45) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL18475748 | 0.78 | HCAR2 (0.38) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL8214792 | 0.77 | ALDH1A1 (0.36) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL18775073 | 0.75 | ALDH1A1 (0.36) | MAPTSMN1; SMN2USP2ALDH1A1POLB | |
| SCHEMBL18872255 | 0.73 | SMN1; SMN2 (0.36) | MAPTSMN1; SMN2USP2ALDH1A1POLB | |
| Tetrahydrofuran SCHEMBL28565880 | 0.72 | ALDH1A1 (0.34) | TSHRSMN1; SMN2USP2ALDH1A1POLB | |
| SCHEMBL16254565 | 0.71 | POLB (0.53) | MAPTALDH1A1POLBL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2017-12-14 | — | — | US | disclosed |
| US-9802900-B2 | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9776960-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9604999-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160332984-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-9458139-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9422279-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160152602-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160083348-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031865-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150141465-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150133430-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-8952171-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275176-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20150141465-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20140275176-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20160332984-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20160083348-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20160152602-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20160031865-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20150133430-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBB, HBG1 | MAPT 4667/4885TSHR 3087/4885SMN1; SMN2 1212/4885 |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.